Semaglutide, a once-weekly GLP-1 receptor agonist, has demonstrated outstanding efficacy: in the STEP 1 trial, adults without diabetes receiving semaglutide 2.4 mg weekly lost on average 14.9% of their baseline body weight by week 68 versus 2.4% with placebo, a treatment difference of 12.4 percentage points [63]. The gene discussed is GLP1R; the disease is diabetes mellitus.